A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Inclusion Criteria: * The subject will participate voluntarily and sign the informed consent form. * Female, aged ≥18 years when signing the informed consent form. * Recurrent or metastatic cervical cancer (pathological types include squamous cell carcinoma, adenocarcinoma) which is not suitable for radical treatment such as surgery and radiotherapy. * At least one measurable lesion is needed. * The Eastern Collaborative Oncology Group (ECOG) physical status score was 0 or 1. * Adequate reserves of organ function is needed. Exclusion Criteria: * Active autoimmune disease. * Central nervous system (CNS) metastasis. * Concomitant diseases such as cardiovascular and cerebrovascular diseases. * Fistula of female genital tract. * Diseases for which systemic corticosteroids or other immunosuppressive agents are planned to be used during the study treatment. * Previous recipients of immune checkpoint inhibitors. * Received systemic antitumor drugs such as chemotherapy and targeted therapy within 4 weeks before the first use of the experimental drug; Received proprietary Chinese medicine with anti-tumor indications within 2 weeks before the first use of the experimental drug. * Received radical concurrent chemoradiotherapy or adjuvant chemoradiotherapy within 12 weeks before the first use of the investigational drug; Received palliative radiotherapy (e.g., reductive radiotherapy for pain or bleeding) or other local treatments (e.g., radiofrequency ablation, transarterial chemoembolization, etc.) within 2 weeks before the first use of the investigational drug. * History of immunodeficiency. * History of allogeneic hematopoietic stem cell transplantation or organ transplantation.